SOPHiA GENETICS (NASDAQ:SOPH) Chairman Jurgi Camblong Sells 20,000 Shares

SOPHiA GENETICS SA (NASDAQ:SOPH) Chairman Jurgi Camblong sold 20,000 shares of the stock in a transaction that occurred on Tuesday, July 21st. The stock was sold at an average price of $6.63, for a total value of $132,600.00. Following the transaction, the chairman directly owned 3,492,822 shares in the company, valued at approximately $23,157,409.86. This represents a 0.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jurgi Camblong also recently made the following trade(s):

• On Monday, July 20th, Jurgi Camblong sold 24,381 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.29, for a total value of $153,356.49.
• On Friday, July 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.62, for a total value of $47,770.00.
• On Tuesday, July 7th, Jurgi Camblong sold 17,685 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.28, for a total value of $93,376.80.
• On Monday, July 6th, Jurgi Camblong sold 22,486 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.25, for a total value of $118,051.50.
• On Thursday, June 25th, Jurgi Camblong sold 1,373 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.70, for a total value of $7,826.10.
• On Friday, June 26th, Jurgi Camblong sold 50,069 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.80, for a total transaction of $290,400.20.
• On Wednesday, June 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.24, for a total transaction of $44,540.00.

SOPHiA GENETICS Stock Down 1.4%

Shares of NASDAQ:SOPH opened at $5.57 on Wednesday. The stock has a market capitalization of $467.27 million, a price-to-earnings ratio of -10.71 and a beta of 0.96. SOPHiA GENETICS SA has a 1-year low of $2.92 and a 1-year high of $6.77. The company’s fifty day moving average is $5.42 and its two-hundred day moving average is $5.09. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.90 and a current ratio of 2.06.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.The business had revenue of $21.69 million during the quarter, compared to the consensus estimate of $20.40 million. Equities analysts anticipate that SOPHiA GENETICS SA will post -0.58 EPS for the current year.

Analysts Set New Price Targets

SOPH has been the subject of several analyst reports. Zacks Research raised shares of SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. BTIG Research reaffirmed a “buy” rating and issued a $8.00 price objective on shares of SOPHiA GENETICS in a report on Monday, June 15th. Finally, HC Wainwright assumed coverage on shares of SOPHiA GENETICS in a research report on Monday, July 20th. They issued a “buy” rating and a $12.00 price objective on the stock. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, SOPHiA GENETICS has a consensus rating of “Hold” and an average target price of $9.00.

Institutional Trading of SOPHiA GENETICS

Several large investors have recently added to or reduced their stakes in SOPH. Hennion & Walsh Asset Management Inc. bought a new stake in SOPHiA GENETICS during the 2nd quarter valued at $567,000. Royal Bank of Canada grew its stake in shares of SOPHiA GENETICS by 3,130.2% in the first quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock worth $96,000 after purchasing an additional 18,781 shares in the last quarter. Sei Investments Co. acquired a new position in shares of SOPHiA GENETICS during the first quarter valued at $1,772,000. Principal Financial Group Inc. raised its stake in shares of SOPHiA GENETICS by 0.7% during the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after purchasing an additional 9,800 shares in the last quarter. Finally, Hodges Capital Management Inc. acquired a new stake in SOPHiA GENETICS in the first quarter worth about $2,157,000. 31.59% of the stock is currently owned by institutional investors and hedge funds.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.